The prevalence of pancreatic cancer has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of cancer, the robust pipeline
Company completes analytical validation study evaluating performance of liquid biopsy test for pancreatic cancerSAN DIEGO (BUSINESS WIRE) Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy tests initially focused on non-invasive.
Cancer Liquid Biopsy Developer Bluestar Raises $70M, Adds Venter to Scientific Advisory Board
May 21, 2021
J. Craig Venter, Ph.D.
Bluestar Genomics, the developer of an epigenomic platform focused on early cancer detection, has raised $70 million in an oversubscribed Series C equity financing and named genomics pioneer J. Craig Venter, Ph.D., among two new members of its expanded scientific advisory board.
“Collectively, these milestones will extend our ability to deliver on our promise to improve on existing cancer screening and provide a new solution where none exists,” Samuel Levy, Ph.D., Bluestar’s CEO and Chief Scientific Officer, said in a statement.
Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, today announced the .
Bluestar Genomics Closes $70M Series C Funding, Expands Scientific Advisory Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.